Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug428 | Azithromycin Tablets Wiki | 0.71 |
| drug1795 | Hydroxychloroquine Sulfate Wiki | 0.29 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment. This study is a phase I clinical trial of booster vaccination of adenovirus type-5 vectored COVID-19 vaccine 6 months after prime vaccination. The investigators intent to evaluate the safety and immunogenicity of booster vaccination of adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged aged 18-60 years.
Description: Occurrence of adverse reactions within 14 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of adverse reactions within 14 days after booster vaccination Time: 0-14 days post-vaccinationDescription: Occurrence of adverse events within 14 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of adverse events within 14 days after booster vaccination Time: 0-14 days post-vaccinationDescription: Occurrence of adverse events within 28 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of adverse events within 28 days after booster vaccination Time: 0-28 days post-vaccinationDescription: Occurrence of serious adverse events within 28 days after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of serious adverse events within 28 days after booster vaccination Time: 0-28 days post-vaccinationDescription: Occurrence of serious adverse events within 6 months after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of serious adverse events within 6 months after booster vaccination Time: 6 months post-vaccinationDescription: Occurrence of serious adverse events within 12 months after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Occurrence of serious adverse events within 12 months after booster vaccination Time: 12 months post-vaccinationDescription: Changes in laboratory test indicators (including white blood cell count, lymphocyte count, neutrophils, platelets, hemoglobin, ALT, AST, total bilirubin, fasting blood glucose, creatinine) before and 1 day after vaccination
Measure: Changes in laboratory test indicators before and 1 day after vaccination Time: 1 day post-vaccinationDescription: Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Antibody of S-RBD at day 14, day 28, month 6 and month 12 after booster vaccination Time: 14 days, 28 days, 6 months and 12 months post-vaccinationDescription: Cellular immunity at day 14 after booster vaccination of adenovirus type-5 vectored COVID-19 vaccine
Measure: Cellular immunity at day 14 after booster vaccination Time: 14 days post-vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports